Michael Tanaka

2.5k total citations · 1 hit paper
21 papers, 1.9k citations indexed

About

Michael Tanaka is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michael Tanaka has authored 21 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Michael Tanaka's work include Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Treatment and Pharmacology (3 papers). Michael Tanaka is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Treatment and Pharmacology (3 papers). Michael Tanaka collaborates with scholars based in United States, India and Canada. Michael Tanaka's co-authors include Margaret von Mehren, A. Kevin Raymond, Vivien Bramwell, George D. Demetri, Ernest C. Borden, John J. Crowley, Robert G. Maki, Cathryn Rankin, Christopher D.�M. Fletcher and Christopher W. Ryan and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology and Cancer Chemotherapy and Pharmacology.

In The Last Decade

Michael Tanaka

19 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

2008 768 citations Charles D. Blanke, Cathryn Rankin et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Tanaka United States	13	767	629	582	576	377	21	1.9k
Aliki Taylor United Kingdom	18	340 0.4×	135 0.2×	613 1.1×	322 0.6×	359 1.0×	50	1.7k
Matthias Schwarzbach Germany	27	1.4k 1.9×	145 0.2×	610 1.0×	727 1.3×	149 0.4×	90	2.2k
Brendan C. Visser United States	36	1.2k 1.5×	212 0.3×	2.0k 3.5×	1.7k 2.9×	88 0.2×	138	3.3k
Kevin G. Billingsley United States	27	1.1k 1.4×	132 0.2×	1.7k 2.9×	1.0k 1.8×	89 0.2×	98	2.9k
Gauri Varadhachary United States	17	663 0.9×	92 0.1×	1.5k 2.7×	504 0.9×	218 0.6×	25	2.1k
Rodolfo Passalacqua Italy	28	1.3k 1.7×	173 0.3×	2.1k 3.6×	948 1.6×	123 0.3×	140	3.7k
Robert T. Osteen United States	30	986 1.3×	326 0.5×	1.2k 2.0×	1.4k 2.4×	168 0.4×	57	3.3k
Oscar Bertetto Italy	26	639 0.8×	48 0.1×	1.2k 2.0×	561 1.0×	160 0.4×	105	2.3k
Niraj J. Gusani United States	29	725 0.9×	111 0.2×	1.1k 1.8×	1.2k 2.0×	54 0.1×	107	2.4k
Tom Crosby United Kingdom	26	1.7k 2.2×	250 0.4×	946 1.6×	1.5k 2.6×	118 0.3×	108	2.6k

Countries citing papers authored by Michael Tanaka

Since Specialization

Citations

This map shows the geographic impact of Michael Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Tanaka more than expected).

Fields of papers citing papers by Michael Tanaka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Tanaka. The network helps show where Michael Tanaka may publish in the future.

Co-authorship network of co-authors of Michael Tanaka

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Tanaka. A scholar is included among the top collaborators of Michael Tanaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Tanaka. Michael Tanaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Damay, Vika, et al.. (2020). Coronavirus disease 2019 and cardiovascular system: A narrative review. IJC Heart & Vasculature. 29. 100557–100557. 98 indexed citations

Semrad, Thomas J., Edward Kim, Michael Tanaka, et al.. (2016). Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy. Cancer Treatment and Research Communications. 10. 21–26. 25 indexed citations

Semrad, Thomas J., Edward Kim, Michael Tanaka, et al.. (2016). Phase II study of dovitinib in patients (Pts) progressing on anti-vascular endothelial growth factor (VEGF) therapy.. Journal of Clinical Oncology. 34(4_suppl). 616–616. 4 indexed citations

Semrad, Thomas J., Afsaneh Barzi, Heinz‐Josef Lenz, et al.. (2014). Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. International Journal of Clinical Oncology. 20(3). 518–524. 24 indexed citations

Ueshima, Kazuomi, Masatoshi Kudo, Michael Tanaka, et al.. (2011). Phase I study of sorafenib in combination with low-dose cisplatin and fluorouracil intra-arterial infusion chemotherapy.. Journal of Clinical Oncology. 29(15_suppl). e14563–e14563. 1 indexed citations

Ho, Cheryl, Randeep Sangha, Laurel Beckett, et al.. (2010). Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study. Investigational New Drugs. 29(4). 680–687. 12 indexed citations

Ramanathan, Ramesh K., Chandra P. Belani, D. A. Singh, et al.. (2009). A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemotherapy and Pharmacology. 64(4). 777–783. 225 indexed citations

Lau, Derick, et al.. (2008). Population-Based Phase I Trial of Irinotecan and Epirubicin. American Journal of Clinical Oncology. 31(3). 226–230. 1 indexed citations

Blanke, Charles D., Cathryn Rankin, George D. Demetri, et al.. (2008). Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. Journal of Clinical Oncology. 26(4). 626–632. 768 indexed citations breakdown →

10.

Davies, Angela M., Cheryl Ho, Laurel Beckett, et al.. (2007). Phase I Study of Two Different Schedules of Bortezomib and Pemetrexed in Advanced Solid Tumors with Emphasis on Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(12). 1112–1116. 19 indexed citations

11.

Wang, Henry E., Janice Ryu, David R. Gandara, et al.. (2007). A Phase II Study of Paclitaxel, Carboplatin, and Radiation with or without Surgery for Esophageal Cancer. Journal of Thoracic Oncology. 2(2). 153–157. 33 indexed citations

12.

Tanaka, Michael, et al.. (2007). Automatic viscosity controlled production of photoresist. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 6519. 65193N–65193N. 1 indexed citations

13.

Whitehead, Robert P., Sheryl McCoy, John S. Macdonald, et al.. (2006). Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study. Investigational New Drugs. 24(4). 335–341. 11 indexed citations

14.

Smalley, Stephen R., Jacqueline Benedetti, Stephen K. Williamson, et al.. (2006). Phase III Trial of Fluorouracil-Based Chemotherapy Regimens Plus Radiotherapy in Postoperative Adjuvant Rectal Cancer: GI INT 0144. Journal of Clinical Oncology. 24(22). 3542–3547. 111 indexed citations

15.

Li, Yueju, Laurel Beckett, Helen K. Chew, et al.. (2004). An Evaluation of Barriers to Accrual in the Era of Legislation Requiring Insurance Coverage of Cancer Clinical Trial Costs in California. The Cancer Journal. 10(5). 294–300. 27 indexed citations

16.

Lim, Nelson, Primo N. Lara, Derick Lau, et al.. (2003). Phase I Trial of Gemcitabine and Paclitaxel in Advanced Solid Tumors. Cancer Investigation. 21(1). 7–13. 6 indexed citations

17.

Hayashida, Kei, Noriaki Kume, Akira Ueda, et al.. (2003). 4P-0979 Serum soluble lectin-like oxidized LDL receptor-1 (soluble LOX-1) as a novel marker for acute coronary syndrome. Atherosclerosis Supplements. 4(2). 289–289.

18.

Tanaka, Michael, et al.. (2002). Premedication Strategy for Weekly Paclitaxel. Cancer Investigation. 20(5-6). 666–672. 29 indexed citations

19.

Lara, Primo N., Roger Higdon, Nelson Lim, et al.. (2001). Prospective Evaluation of Cancer Clinical Trial Accrual Patterns: Identifying Potential Barriers to Enrollment. Journal of Clinical Oncology. 19(6). 1728–1733. 480 indexed citations

20.

Perez, Edith A., et al.. (1991). Weekly 24-Hour Continuous Infusion Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma: A Phase I Study. Journal of Immunotherapy. 10(1). 57–62. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact